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Abstract
Background: Streptococcal infections are known to trigger autoimmune disorders, affecting millions worldwide. Recently,
we found an association between post-streptococcal autoantibodies against Protein Disulphide Isomerase (PDI), an enzyme
involved in insulin degradation and insulin resistance. This led us to evaluate associations between post-streptococcal
antibodies and metabolic syndrome, as defined by the updated National Cholesterol Education Program definition, 2005.
Methods and Findings: Metabolic data (HDL, triglycerides, fasting glucose, blood pressure, waist circumference, BMI,
smoking), post-streptococcal antibodies (anti-Streptolysin O (ASO) and anti-PDI), and C-reactive protein (CRP, as a general
inflammatory marker), were assessed in 1156 participants of the Wisconsin Sleep Cohort Study. Anti-PDI antibodies were
found in 308 participants (26.6%), ASO$100 in 258 (22.3%), and 482 (41.7%) met diagnostic criteria for metabolic syndrome.
Anti-PDI antibodies but not ASO were significantly associated with metabolic syndrome [n=1156, OR 1.463 (95% CI 1.114,
1.920), p=0.0062; adjusted for age, gender, education, smoking]. Importantly, the anti-PDI - metabolic syndrome
association remained significant after adjusting for CRP and fasting insulin.
Conclusions: Post-streptococcal anti-PDI antibodies are associated with metabolic syndrome regardless of fasting insulin
and CRP levels. Whereas these data are in line with a growing body of evidence linking infections, immunity and
metabolism, additional studies are necessary to establish the post-streptococcal – metabolic syndrome association.
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Introduction
Metabolic syndrome is characterized by a cluster of metabolic
risk factors for cardiovascular diseases and type 2 diabetes that
include abdominal obesity, dyslipidemia, hypertension, insulin
resistance, prothrombotic and proinflammatory state. Other
conditions associated with the syndrome include physical inactiv-
ity, aging, hormonal imbalance and genetic predisposition.
Approximately 25% of the adult US population meet criteria for
the metabolic syndrome [1,2].
In a recent study, we reported that a subset of patients with post-
streptococcal immunity, as defined by the presence of anti-
Streptolysin O (ASO) or anti-DNase B (ADB) antibodies also carry
auto-antibodies against Protein Disulfide Isomerase (PDI), a
pleiotropic enzyme. We found that these auto-antibodies neutral-
ize PDI, decrease insulin degradation and correlate with higher
insulin levels and insulin resistance [3]. PDI catalyzes disulfide
bonds formation, breakage and rearrangement [4]. Extracellular
PDI is involved in several metabolic pathways including insulin
degradation [5,6], platelet aggregation and secretion [7], fibrin
formation [8,9,10] and intracellular nitric oxide delivery [11]. In
addition to its role in disulfide bond formation, PDI is involved in
regulating NAD(P)H oxidase [12] and is also the smaller subunit of
microsomal triglyceride transfer protein which catalyzes the
assembly of apoB containing lipoproteins in the liver and intestinal
cells [13]. Cell surface PDI can also bind estradiol and tri-
iodotyronine and may impact on the hormone-receptor interac-
tion [14].
Interestingly, two types of anti-PDI autoantibodies were
found in our prior study, one with higher affinity for the
h u m a nP D Iv e r s u st h eb o v i n eP D Ip r o t e i n ,a n das e c o n d
antibody with the opposite profile. Although the presence of
these antibodies correlated only partially with each other, they
both were highly correlated with ASO, suggesting that they are
part of a spectrum of common post-streptococcal immune
response [3]. Furthermore, we found that the binding sites of
the bovine and human PDI have a strong structural similarity
with a specific sequence in the streptococcal toxin Streptolysin
O indicative of molecular mimicry, initiated by the ASO
response.
In the current study, we further assessed associations between
immunity and metabolism and explored whether post-streptococ-
cal immune status is associated with metabolic alterations beyond
insulin resistance.
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Ethics Statement
The institutional review board of the University of Wisconsin
Medical School approved all protocols for the study and a written
informed consent was obtained from all participants.
Subjects
The Wisconsin Sleep Cohort Study is an ongoing longitudinal
study in which metabolic, sleep data and blood samples are
obtained every four years for each participant [15].
Briefly: to construct a defined sampling frame, all employees
aged 30–60 y of four state agencies in south central Wisconsin
were mailed in 1989 a survey on sleep habits, health, and
demographics. Mailed surveys were repeated at 5-y intervals and
based on that survey new participants were added between 1989–
2000. A 71% response rate (n=4896) was obtained from this
mailed survey. A stratified random sample of respondents
(n=3028) was then recruited. Stratification was based on risk
for sleep-disordered breathing (SDB), with an oversampling of
habitual snorers to ensure an adequate distribution of SDB.
Exclusion criteria included pregnancy, unstable cardiopulmonary
disease, airway cancers, and recent upper respiratory tract surgery.
The baseline response rate was 51% (n=1545), with most refusals
due to the inconvenience of sleeping away from home required for
the polysomnogram. Collection of morning, fasted blood was
added to the protocol in 1993. Follow-up studies have been
conducted at 4-y intervals. Data to define metabolic syndrome was
collected at all overnight studies (baseline and at the 4 year follow-
ups) including: measurements of waist girth and blood pressure, an
interview where participants report prescription drug use and
doctor diagnosed diabetes and blood samples were obtained for
triglycerides, HDL and glucose. Insulin, CRP and post-strepto-
coccal antibodies were assessed at a later date on banked sera.
Extensive survey and other data available from the sampling frame
have been used to evaluate the potential for response and drop out
biases. The most recent 4 year follow-up for this paper was in 2009
and the average 4 year follow-up participation rates are 80%;
among those lost to follow up were 104 deceased individuals, 17
due to undeliverable addresses, 6 who asked not to be called again
and 5 for medical reasons. All available visits (serum samples) were
used for the current study and included a total of 2,471 visits of
1156 participants. [Mean age at blood draw 5568.6 (SD); range
34.9–78.2 years; 45.7% females, 97.1% Caucasians, 1.1% Asians,
0.9% African -Americans].
Metabolic syndrome
The criteria used to diagnose metabolic syndrome were those
proposed by the National Cholesterol Education Program (NCEP)
Adult Treatment Panel III (ATP III), and revised by the American
Heart Association (AHA) and the National Heart, Lung, and Blood
Institute (NHLBI) [16]. At least three of the following criteria were
mandatory for diagnosis: (a) Elevated waist circumference: Men:
$102 cm ; Women: $88 cm; (b) Elevated triglycerides: $150 mg/
dL or on drug treatment for elevated triglycerides; (c) Reduced
HDL cholesterol: Men: ,40 mg/dL; Women: ,50 mg/dL or on
drug treatment for reduced HDL-C ; (d) Elevated blood pressure:
$130/85 mm Hg or on antihypertensive drug treatment in a
patient with a history of hypertension; (e) Elevated fasting glucose:
$100 mg/dL or on drug treatment for elevated glucose.
Antibodies and reagents
Bovine PDI and rabbit polyclonal anti-bovine PDI antibody
(cross-reacting with rat and human PDI) were obtained from
Invitrogen. Recombinant human PDI protein was obtained from
Assay Designs.
Assays. ASO and CRP were assessed using commercially
available kits (SeraTest ASO, Remel KS, USA; CRP ELISA,
Alpha Diagnostic International, TX, USA) according to the
manufacturer’s instructions.
Anti-PDI score. The presence of anti-human and anti-bovine
PDI autoantibodies were determined using in house ELISA, and
subjects positive for either human or bovine PDI were considered
PDI positive. Microtiter plates (96 wells) were coated with bovine
(100 ml of 1.5 mg/mL) or recombinant human (100 mlo f5mg/
mL) PDI (incubated at 4uC, 24 hours). Plates were rinsed and
flicked 36(0.05% Triton in PBS), blocked (5% nonfat dry milk in
PBS), and exposed to human sera diluted in 5% milk (90 min,
room temperature). Anti-bovine PDI antibodies were detected
using a 1:250 dilution; anti-human PDI antibodies using a 1:50
dilution. These dilutions are compatible with high and low affinity
antibodies respectively. Donkey anti-human IgG-HRP (Jackson
ImmunoResearch Laboratories, 1:10,000) was used as the
secondary antibody. To detect antibody–antigen interactions
tetramethylbenzidine (TMB, Vector Laboratories) was added
(reaction stopped at 5 min with 50 ml H3PO4 (1 M)), and the
resulting signal read at 450 nm (Molecular Devices EMAX micro
plate reader). The cutoff for positive was OD$0.5 for anti-bovine
PDI and OD$0.75 for anti-human PDI (due to higher
background). All samples were assayed in duplicate.
Statistical analysis
All analyses were performed with SAS software (version 8.02;
SAS Institute Inc, Cary, NC). For comparison of demographic
characteristics between the PDI positive and negative individuals,
we used t-tests and Chi-square tests. For modeling continuous
outcomes, such as waist girth mean, we use generalized linear
models and PDI status as the predictor variable, adjusted for age,
sex, smoking status, and education. There was one continuous
variable that was not normally distributed. For this variable, CRP,
we used a log transformation. For modeling binary variables, such
as metabolic Syndrome, we used logistic regression with PDI status
as the predictor, adjusted for age, sex, smoking status, and
education. Resulting estimated effects (odds ratios/least square
means) were calculated from the beta coefficients of these models.
P-values of 0.05 were considered statistically significant.
Results
Anti-PDI is associated with metabolic syndrome
Table 1 includes the characteristics of the cohort sample at
baseline (n=1156 subjects), stratified by anti-PDI status. Antibod-
ies against bovine or human PDI were found in 26.6% of the
subjects (n=308) with some predominance for younger individ-
uals, males and higher socio-economic status. Participants who
were positive for anti-PDI antibodies were more likely to meet the
diagnostic criteria for metabolic syndrome [OR 1.463 (95% CI
1.114, 1.920), p=0.0062; adjusted for age, gender, education,
smoking].
Significant associations between anti-PDI antibodies status and
single components of metabolic syndrome were found for reduced
HDL-C and raised fasting glucose.
CRP results were available for 985 of the 1156 participants.
Both mean CRP values and positive status were not higher in anti-
PDI positive participants (Table 1), suggesting a specific immune
response against PDI rather than a generalized immune
activation. The association between anti-PDI antibodies and
metabolic syndrome in these 985 subjects was significant after
Post-Streptococcal Metabolic Syndrome
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CI 1.1, 2.0), p=0.0116]. Adjusting the results also for log (CRP)
didn’t have a noticeable effect [OR 1.5 (95% CI 1.1, 2.0),
p=0.0176], indicating that CRP is not a significant mediator in
the anti-PDI – metabolic syndrome association.
Of 1156 participants, 1118 subjects had a second assessment in
a 4 year interval. More than half of the subjects with positive anti-
PDI status in the first visit were still positive in the second visit 4
years later (Table 2), suggesting a relatively long lasting process
with a potential for prolonged metabolic alterations.
The anti-PDI – metabolic syndrome association is not
dependant on fasting insulin values
In a former study we demonstrated an association between anti-
human PDI antibodies, fasting insulin and insulin resistance [3]. In
the current study we found an association between anti-PDI
(human and/or bovine) and metabolic syndrome. Adjusting the
results for fasting insulin had no effect on the association [n=985,
OR (95% CI)=1.5 (1.1, 2.1), p=0.0145, compared to OR (95%
CI)=1.5 (1.1, 2.0), p=0.0116 before adjustment], suggesting that
anti-PDI antibodies are associated with metabolic alterations
beyond insulin resistance.
Anti-Streptolysin O (ASO) is not significantly associated
with metabolic syndrome
At the first visit of the 1156 subjects, ASO$100 was found in
258 cases (22.3%) with mild predominance in younger age and
women. A value over 100 IU was considered positive for this age
group [17]. Participants who were ASO positive had some
tendency toward lower HDL and larger waist circumference and
Table 1. Baseline demographic and metabolic characteristics, stratified by anti-PDI status (n=1156 subjects).
Negative for anti-PDI
* (n=848) Positive for anti-PDI
{ (n=308) p-value
Age 52.7 (7.9) 52.0 (7.0) 0.1354
Male Sex 454 (54%) 171 (56%) 0.5500
BMI 31.0 (6.8) 31.4 (7.0) 0.3858
Smoking
Never 400 (47%) 164 (53%) 0.1625
Past 325 (38%) 101 (33%)
Current 123 (15%) 43 (14%)
At least some college education 632 (75%) 236 (77%) 0.4665
Abdominal obesity
{ REF 1.26 (0.96, 1.66) 0.0925
Raised Triglycerides
{ REF 1.21 (0.93, 1.58) 0.1636
Reduced HDL
{ REF 1.37 (1.05, 1.79) 0.0199
Hypertension
{ REF 1.29 (0.98, 1.69) 0.0685
Raised fasting glucose
{ REF 1.33 (1.01, 1.76) 0.0457
Metabolic Syndrome
{ REF 1.46 (1.11, 1.92) 0.0062
Log (CRP (mg/dL))
{,1 1.08 (0.04) 1.12 (0.06) 0.5957
CRP.3 mg/dL
{,1 REF 1.01 (0.75, 1.36) 0.9440
CRP.10 mg/dL
{,1 REF 1.03 (0.61, 1.74) 0.9246
Insulin (iu/ml)
{,1 12.0 (0.37) 12.3 (0.60) 0.6078
Results are presented as: mean (SD), number of subjects (%) or as Odds Ratio (95% Confidence Interval).
*Negative for both human PDI and Bovine PDI.
{Positive for bovine PDI and/or human PDI.
{Adjusted for age, sex, education, and smoking.
1Reduced sample size (n=985).
doi:10.1371/journal.pone.0025017.t001
Table 2. Stability of anti-streptococcal antibodies status across time.
First visit results Second visit results
ASO,100 ASO$100 Anti-PDI negative
* Anti-PDI positive
{
ASO,100 (n=879) 831 (95%) 48 (5%)
ASO$100 (n=239) 154 (64%) 85 (36%)
Anti-PDI negative
* (n=824) 739 (90%) 85 (10%)
Anti-PDI positive
{ (n=294) 134 (46%) 160 (54%)
1118 individuals had 2 subsequent visits in a 4-year interval. Results in the second visit are stratified by the first visit results.
*Negative for both human PDI and Bovine PDI;
{Positive for bovine PDI and/or human PDI.
doi:10.1371/journal.pone.0025017.t002
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syndrome but the results were not significant [OR 1.116 (95% CI
0.835, 1.491), p=0.4597, adjusted for age, gender, education and
smoking]. CRP values were not significantly more elevated in
ASO positive subjects.
As previously reported [3], we found that the presence of anti-
PDI antibodies (human or bovine PDI) correlated with ASO
(Kappa=0.2443, p,0.0001, n=2471). At the first visit of the
1156 subjects, 119 (10.3%) were positive for both post-streptococ-
cal antibodies: anti-PDI and ASO, 328 (28.4%) were positive for
one of them, and 709 participants (61.3%) were negative for both
antibodies. Combinations of anti-PDI and ASO (Participants who
were positive for both or those who were positive for at least one,
compared to participants who were negative for both) did not
demonstrate a greater association with metabolic syndrome
compared to only anti-PDI.
Discussion
In this study we found a positive association between the
presence of post-streptococcal antibodies (anti-bovine PDI and/or
anti-human PDI) and metabolic syndrome. The association was
independent of socioeconomic correlates, CRP as a marker of
general immune activation and fasting insulin levels. This study
bolsters our former finding of positive association between anti-
human PDI and insulin resistance, an association we postulated to
be due to the inhibition of PDI mediated insulin degradation [3].
This is also not the first time that metabolic syndrome is
suggested to have a post infectious component. Several pathogens
have been reported to cause obesity in animal models [18,19], and
Vijay-Kumar et al suggested interactions between the immune
system and the gut microbiota as both necessary and sufficient for
the development of metabolic syndrome in mice [20]. These
findings are also in line with the well known importance of
inflammatory mechanisms in metabolic syndrome [21,22,23,24].
Indeed, though this study indicates that metabolic syndrome could
have a post-streptococcal component, other infections might be
involved as well and should be assessed in future studies.
Our results suggest that anti-PDI antibodies are associated, to a
certain degree, with each of the 5 components in the definition of
metabolic syndrome, but significant associations were found only
with reduced HDL-C and raised fasting glucose. The mechanism
by which post-streptococcal immunity alters the risk of metabolic
syndrome and its individual components is unknown and could be
multi-factorial. Nonetheless, our results suggest that autoimmunity
directed toward the PDI enzyme may be one of the mechanisms
involved, and considering the pleiotropic role of PDI, it is an
intriguingly strong candidate. PDI is a multifunctional enzyme
that regulates critical steps in various metabolic processes
[5,6,7,8,9,10,11,25] and anti-PDI antibodies have been shown to
also have pro and anti-thrombotic effects [26,27]. However, the
causal role of immunity in metabolic syndrome and particularly
the role of anti-PDI antibodies needs to be further explored.
Our study suffers from several important limitations. First, our
data suggest that post-streptococcal immune changes remain
relatively stable across time, lasting years, but this will need to be
further studied following documented streptococcal infections.
Additionally, the prevalence of metabolic syndrome in our cohort
is higher than usually reported and may reflect oversampling of
habitual snorers, among whom there is a higher prevalence of
metabolic syndrome. Other limitations of the current study are
limited information on other confounding factors for metabolic
syndrome such as diet and exercise habits.
Finally, since metabolic syndrome is a leading cause of
morbidity and mortality in the developed world, and these study
findings could be of importance for public health, independent
replications of the results in other populations by other research
groups are definitely needed.
Indeed, if replicated, our results may also have implications for
the prevention of metabolic syndrome. The first-line interventions
to reduce metabolic risk factors are lifestyle changes including
weight loss, increased physical activity and healthy eating habits.
While these are recommended for the entire population,
identifying specific risk groups, such as those with post-strepto-
coccal immunity, may lead to targeted approach and better
compliance.
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